Related Experiment Video
Updated: Apr 21, 2026
14:39
A Simple and Rapid Method for Simultaneous Isolation of Primary Islets and Primary Pancreatic Acinar Cells from Mice
Published on: January 9, 2026
1.0K
Sitagliptin-induced pancreatitis - a longer road than expected
Matthew Nelson1, Niyati Bhandari2, Jill Wener3
1Department of Internal Medicine- Rush University Medical Center, Roosevelt University College of Pharmacy 1400 N Roosevelt Blvd, Schaumburg, Illinois, 60173.
Clinical Case Reports
|October 31, 2014
Summary
Sitagliptin, a medication for type 2 diabetes, can cause pancreatitis at any time during treatment. Patients experiencing pancreatitis symptoms should stop sitagliptin and switch to an alternative diabetes management plan.
Area of Science:
- Endocrinology
- Pharmacology
- Gastroenterology
Background:
- Sitagliptin is a widely prescribed dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes management.
- Pancreatitis is a potential adverse effect associated with DPP-4 inhibitors.
- The timing of sitagliptin-induced pancreatitis onset is not fully characterized.
Purpose of the Study:
- To highlight the potential for sitagliptin to induce pancreatitis.
- To inform clinicians about the timing and management of sitagliptin-induced pancreatitis.
Main Methods:
- This is a clinical message based on observed adverse events.
- No specific study methodology was detailed in the abstract.
Main Results:
- Sitagliptin-induced pancreatitis can manifest at any point during therapy, including years after initiation.
- Early recognition and discontinuation of sitagliptin are crucial for managing pancreatitis.
Conclusions:
- Clinicians should maintain a high index of suspicion for pancreatitis in patients taking sitagliptin.
- Immediate cessation of sitagliptin and initiation of alternative diabetes treatment are recommended upon diagnosis of pancreatitis.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
997
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
997
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
1.1K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
982
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
982
01:21Acute Pancreatitis II: Pathophysiology
25
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
25